AGARWALEYE · NSE
Dr. Agarwal's Health Care Limited
₹553.4
+0.05% (+₹0.3)
Prev. close
₹553.1
Volume
86,094
Delivery %
51.8%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Upgraded Dr. Agarwal's Health Care to 'buy' from 'hold' on August 5, with a target of ₹600 per share, indicating a 19.6%…” | Jefferies AnalysisJefferies | Dr. Agarwal's Health Care | PENDING | |
| “Recommends buying Dr. Agarwal's Health Care at ₹533 with a target of ₹575 and a stop loss at ₹515, based on a breakout s…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care Ltd. | MISS | |
| “Recommends buying Dr. Agarwal's Health Care at ₹506, targeting ₹545, with a stop loss at ₹488, based on a breakout strat…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care Ltd. | MISS | |
| “Recommends buying Dr. Agarwal's Health Care at ₹524, targeting ₹560 with a stop loss at ₹505, as a breakout stock for to…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care | MISS | |
| “Recommends buying Dr. Agarwal's Health Care at ₹506, targeting ₹545, with a stop loss at ₹490, based on a breakout strat…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care Ltd | HIT | |
| “Recommends buying Dr. Agarwal's Health Care at ₹506 with a target of ₹550 and a stop loss at ₹490, based on breakout sig…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care | MISS | |
| “Bullish on Dr. Agarwal's Health Care, recommending a buy at ₹508 with a target of ₹545 and a stop loss at ₹490.” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care Ltd. | HIT | |
| “Bullish on Dr. Agarwal's Health Care, recommending a buy at ₹488 with a target of ₹525 and a stop loss at ₹470, based on…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care Ltd. | NOT TRIGGERED | |
| “Bullish on Dr. Agarwal's Health Care Ltd, recommending a buy between ₹478–485 with a target price of ₹550 in two to thre…” | Marketsmith India AnalysisMarketsmith India | Dr. Agarwal's Health Care Ltd | NOT TRIGGERED | |
| “Recommends buying Dr. Agarwal's Health Care at ₹433, targeting ₹465 with a stop loss at ₹418, based on technical breakou…” | Sumeet BagadiaChoice Equity Broking | Dr. Agarwal's Health Care Ltd. | HIT | |
| “Initiated coverage on Dr Agarwal's Health Care with an 'Add' rating and a target price of ₹425, implying a 7.6% potentia…” | Kotak Institutional Equities AnalysisKotak Institutional Equities | Dr Agarwal's Health Care Ltd | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Advises investors to avoid investing in Dr. Agarwal's Health Care shares in the short term due to a flat debut, modest I…” | Sagar ShettyStoxBox | Dr. Agarwal's Health Care | — |
Fundamentals
About Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Dr. Adil Agarwal M.B.B.S, M.S, MBA
Headquarters
Chennai
Website
dragarwals.co.inExchange
View on NSE ↗Key stats
Market cap
₹16,448.26 Cr
P/E ratio (TTM)
111.6
Dividend yield
0.00%
EPS (TTM)
₹4.65
Beta (1Y · daily vs NIFTY 50)
0.30
Shares float
12.12 Cr
EPS · quarter ended Jun 2026
₹1.42
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (revenue was nil or not reported).
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
Cash for FY25: the figure the company printed, which its own totals confirm and the series' figure did not.
08 · Profit & Loss — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹1,376.45 Cr | ₹1,757.02 Cr | ₹2,124.52 Cr | |
| ₹1,235.88 Cr | ₹1,594.15 Cr | ₹1,877.21 Cr | |
Profit before exceptional items and Tax | ₹140.57 Cr | ₹162.87 Cr | ₹247.31 Cr |
a) Provision for Impairment on Goodwill | — | ₹3.02 Cr | — |
b) Fair Value Change in financial instruments | — | — | ₹-1.33 Cr |
Profit before tax | ₹140.57 Cr | ₹159.85 Cr | ₹248.64 Cr |
| ₹45.52 Cr | ₹49.51 Cr | ₹80.50 Cr | |
| ₹85.54 Cr | ₹109.83 Cr | ₹185.74 Cr | |
Profit for the year | ₹95.05 Cr | ₹110.34 Cr | ₹168.14 Cr |
| ₹-9.51 Cr | ₹-51.00 L | ₹17.60 Cr | |
Owners of the company | ₹83.06 Cr | ₹83.46 Cr | ₹133.19 Cr |
Non controlling interests | ₹11.99 Cr | ₹26.88 Cr | ₹34.95 Cr |
Subtotal‡ | ₹95.05 Cr | — | — |
Total | — | ₹110.34 Cr | ₹168.14 Cr |
Owners of the company | ₹-9.53 Cr | ₹-56.00 L | ₹17.59 Cr |
Non controlling interests | ₹2.00 L | ₹5.00 L | ₹1.00 L |
Subtotal‡ | ₹-9.51 Cr | — | — |
Total | — | ₹-51.00 L | ₹17.60 Cr |
Owners of the company | ₹73.53 Cr | ₹82.90 Cr | ₹150.78 Cr |
Non controlling interests | ₹12.01 Cr | ₹26.93 Cr | ₹34.96 Cr |
Subtotal‡ | ₹85.54 Cr | — | — |
Total | — | ₹109.83 Cr | ₹185.74 Cr |
Basic (in) | 3.14 | 2.80 | 4.21 |
Diluted (in) | 3.13 | 2.78 | 4.18 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
‡ The company printed this figure on a line with no label (a bare subtotal under a block). Where the lines above add up to it, it is named after them; otherwise it is shown as “Unlabelled line”. The figure is the company’s own.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹2,752.82 Cr | ₹3,671.57 Cr | ₹3,941.75 Cr | |
| ₹1,994.24 Cr | ₹2,882.97 Cr | ₹3,368.78 Cr | |
| ₹758.58 Cr | ₹788.60 Cr | ₹572.97 Cr | |
| ₹1,373.31 Cr | ₹1,744.75 Cr | ₹1,822.05 Cr | |
| ₹1,339.41 Cr | ₹1,866.59 Cr | ₹2,025.46 Cr | |
Non controlling interest | ₹40.10 Cr | ₹60.23 Cr | ₹94.24 Cr |
Total equity (A) | ₹1,379.51 Cr | ₹1,926.82 Cr | ₹2,119.70 Cr |
| ₹973.51 Cr | ₹1,266.99 Cr | ₹1,360.57 Cr | |
| ₹399.80 Cr | ₹477.76 Cr | ₹461.48 Cr | |
Total equity and liabilities (A+B+C) | ₹2,752.82 Cr | ₹3,671.57 Cr | ₹3,941.75 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹346.00 Cr | ₹357.13 Cr | ₹518.99 Cr | |
| ₹-913.91 Cr | ₹-750.33 Cr | ₹-308.45 Cr | |
| ₹111.75 Cr | ₹100.40 Cr | ₹90.55 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Feb 25–Mar 25(2Q) | Jun 25–Sep 25(2Q) | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| Promoter | 32.45% | 32.42% | 32.39% | 32.36% | 32.34% |
| Public | 67.55% | 67.58% | 67.61% | 67.64% | 67.66% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Dr. Agarwal's Health Care Limited | ₹16,543.38 Cr | ₹523.5 | 112.0 | 8.17 | 6.6% | 0.53 | +21.9% | +1.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Dr Agarwal’s Eye Hospital Merges with Dr Agarwal’s Health Care to Unify Corporate Structure
Digital Health News · 3 days ago